Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator‐activated receptor α modulator (SPPARMα), versus placebo in patients with non‐alcoholic fatty liver disease

Alcoholic Fatty Liver ◽

Sodium Butyrate Ameliorates High-Fat-Diet-Induced Non-alcoholic Fatty Liver Disease through Peroxisome Proliferator-Activated Receptor α-Mediated Activation of β Oxidation and Suppression of Inflammation

Journal of Agricultural and Food Chemistry ◽

10.1021/acs.jafc.8b01189 ◽

2018 ◽

Vol 66 (29) ◽

pp. 7633-7642 ◽

Cited By ~ 22

Author(s):

Bo Sun ◽

Yimin Jia ◽

Jian Hong ◽

Qinwei Sun ◽

Shixing Gao ◽

...

Keyword(s):

Liver Disease ◽

Fatty Liver ◽

Sodium Butyrate ◽

High Fat Diet ◽

Fatty Liver Disease ◽

Peroxisome Proliferator ◽

High Fat ◽

Alcoholic Fatty Liver ◽

C161T and Pro12Ala Polymorphisms of Peroxisome Proliferator—Activated Receptor-g Gene in Asian Indians with Non-alcoholic Fatty Liver Disease

Journal of Clinical and Experimental Hepatology ◽

10.1016/s0973-6883(11)60063-7 ◽

2011 ◽

Vol 1 (1) ◽

pp. 29

Author(s):

SP Bhatt ◽

P Nigam ◽

A Misra ◽

R Guleria ◽

K Luthra ◽

...

Keyword(s):

Liver Disease ◽

Fatty Liver ◽

Fatty Liver Disease ◽

Asian Indians ◽

Peroxisome Proliferator ◽

Alcoholic Fatty Liver ◽

Placebo-controlled, randomised clinical trial: high-dose resveratrol treatment for non-alcoholic fatty liver disease

Scandinavian Journal of Gastroenterology ◽

10.3109/00365521.2015.1107620 ◽

2016 ◽

Vol 51 (4) ◽

pp. 456-464 ◽

Cited By ~ 61

Author(s):

Sara Heebøll ◽

Martin Kreuzfeldt ◽

Stephen Hamilton-Dutoit ◽

Marianne Kjær Poulsen ◽

Hans Stødkilde-Jørgensen ◽

...

Keyword(s):

Clinical Trial ◽

Liver Disease ◽

Fatty Liver ◽

Fatty Liver Disease ◽

Randomised Clinical Trial ◽

High Dose ◽

Alcoholic Fatty Liver ◽

Resveratrol Treatment ◽

Association of peroxisome proliferator activated receptor-γ gene with non-alcoholic fatty liver disease in Asian Indians residing in north India

Gene ◽

10.1016/j.gene.2012.09.067 ◽

2013 ◽

Vol 512 (1) ◽

pp. 143-147 ◽

Cited By ~ 19

Author(s):

Surya Prakash Bhatt ◽

Priyanka Nigam ◽

Anoop Misra ◽

Randeep Guleria ◽

Kalpana Luthra ◽

...

Keyword(s):

Liver Disease ◽

Fatty Liver ◽

Fatty Liver Disease ◽

Asian Indians ◽

North India ◽

Peroxisome Proliferator ◽

Alcoholic Fatty Liver ◽

New peroxisome proliferator-activated receptor agonists: potential treatments for atherogenic dyslipidemia and non-alcoholic fatty liver disease

Expert Opinion on Pharmacotherapy ◽

10.1517/14656566.2014.876992 ◽

2014 ◽

Vol 15 (4) ◽

pp. 493-503 ◽

Cited By ~ 114

Author(s):

Amirhossein Sahebkar ◽

Gerard T Chew ◽

Gerald F Watts

Keyword(s):

Liver Disease ◽

Fatty Liver ◽

Fatty Liver Disease ◽

Atherogenic Dyslipidemia ◽

Peroxisome Proliferator ◽

Alcoholic Fatty Liver ◽

Receptor Agonists ◽

Pro12Ala substitution in the peroxisome proliferator-activated receptor gamma (PPARγ) gene and non-alcoholic fatty liver disease

Archives of Biological Sciences ◽

10.2298/abs1303809c ◽

2013 ◽

Vol 65 (3) ◽

pp. 809-814 ◽

Cited By ~ 1

Author(s):

Shao-Hua Chen ◽

Lixiong Ying ◽

Chenjiao Wu ◽

Qunyan Wang ◽

You-Ming Li

Keyword(s):

Liver Disease ◽

Fatty Liver ◽

Fatty Liver Disease ◽

Peroxisome Proliferator ◽

Alcoholic Fatty Liver ◽

Pparγ Gene ◽

Therapeutic Potential of Peroxisome Proliferator-Activated Receptor Modulation in Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis

Nuclear Receptor Research ◽

10.11131/2017/101310 ◽

2017 ◽

Vol 4 ◽

Cited By ~ 8

Author(s):

Leonie Gellrich ◽

Daniel Merk

Keyword(s):

Liver Disease ◽

Fatty Liver ◽

Fatty Liver Disease ◽

Therapeutic Potential ◽

Peroxisome Proliferator ◽

Alcoholic Fatty Liver ◽

Alcoholic Steatohepatitis ◽

Receptor Modulation ◽

Randomised clinical trial: A phase 2 double‐blind study of namodenoson in non‐alcoholic fatty liver disease and steatohepatitis

Alimentary Pharmacology & Therapeutics ◽

10.1111/apt.16664 ◽

2021 ◽

Author(s):

Rifaat Safadi ◽

Marius Braun ◽

Adi Francis ◽

Yael Milgrom ◽

Muhammad Massarwa ◽

...

Keyword(s):

Clinical Trial ◽

Liver Disease ◽

Fatty Liver ◽

Fatty Liver Disease ◽

Randomised Clinical Trial ◽

Double Blind Study ◽

Phase 2 ◽

Double Blind ◽

Alcoholic Fatty Liver ◽

Oxymatrine ameliorates non-alcoholic fatty liver disease in rats through peroxisome proliferator-activated receptor-α activation

Molecular Medicine Reports ◽

10.3892/mmr.2013.1512 ◽

2013 ◽

Vol 8 (2) ◽

pp. 439-445 ◽

Cited By ~ 18

Author(s):

LIJUAN SHI ◽

LEI SHI ◽

HEFANG ZHANG ◽

ZHIJUAN HU ◽

CHAO WANG ◽

...

Keyword(s):

Liver Disease ◽

Fatty Liver ◽

Fatty Liver Disease ◽

Peroxisome Proliferator ◽

Alcoholic Fatty Liver ◽

Nimesulide, a cyclooxygenase-2 selective inhibitor, suppresses obesity-related non-alcoholic fatty liver disease and hepatic insulin resistance through the regulation of peroxisome proliferator-activated receptor γ

International Journal of Molecular Medicine ◽

10.3892/ijmm.2016.2674 ◽

2016 ◽

Vol 38 (3) ◽

pp. 721-728 ◽

Cited By ~ 12

Author(s):

Shunsuke Tsujimoto ◽

Manabu Kishina ◽

Masahiko Koda ◽

Yasutaka Yamamoto ◽

Kohei Tanaka ◽

...

Keyword(s):

Insulin Resistance ◽

Liver Disease ◽

Fatty Liver ◽

Fatty Liver Disease ◽

Selective Inhibitor ◽

Hepatic Insulin Resistance ◽

Peroxisome Proliferator ◽

Alcoholic Fatty Liver ◽